Pacific Capital Wealth Advisors Inc. Invests $28,000 in Kenvue Inc. (NYSE:KVUE)

Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,291 shares of the company’s stock, valued at approximately $28,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Clearstead Advisors LLC purchased a new stake in shares of Kenvue in the 3rd quarter worth approximately $25,000. Planned Solutions Inc. bought a new position in shares of Kenvue during the fourth quarter valued at $27,000. Venturi Wealth Management LLC purchased a new position in shares of Kenvue in the 3rd quarter worth about $28,000. EverSource Wealth Advisors LLC bought a new position in Kenvue in the 3rd quarter worth about $28,000. Finally, Cullen Frost Bankers Inc. bought a new stake in Kenvue during the 3rd quarter valued at about $29,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE traded up $1.00 during trading hours on Tuesday, hitting $20.08. 30,039,559 shares of the stock were exchanged, compared to its average volume of 17,047,490. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The firm has a fifty day moving average price of $19.85 and a 200-day moving average price of $20.11.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts predict that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend is Tuesday, May 7th.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Sanford C. Bernstein began coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Royal Bank of Canada reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.